Editorial board member, Eleni Andreopoulou, from Weill Cornell Medical College in New York, US, discusses molecular subtyping and advances in molecularly-targeted therapy in triple-negative breast cancer.
Q1. What are the major challenges of treating triple-negative breast cancer? (0:11)
Q2. How have advances in molecular subtyping impacted on the treatment of triple negative-breast cancer? (1:50)
Q3. What unmet needs remain in molecularly targeted breast cancer therapy? (2:36)
Q4. What innovations in clinical trial design are facilitating the development of therapies for high-risk, early-stage breast cancer? (3:41)
Speaker disclosures: Eleni Andreopoulou has nothing to disclose in relation to this video interview.
Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018
